CONTEXT: Whether endogenous sex hormones (ESH) [SHBG, estradiol, testosterone, and dehydroepiandrosterone (DHEA)] are altered by intensive lifestyle modification (ILS) or metformin and whether such changes affect glucose levels among dysglycemic postmenopausal women is unclear. OBJECTIVES: Our objective was to examine intervention impact on ESH and associations with fasting plasma glucose (FPG) and 2-h glucose changes among postmenopausal glucose-intolerant women. DESIGN: We performed a secondary analysis of a randomized controlled trial. PARTICIPANTS: Participants included postmenopausal, overweight, glucose-intolerant women not using exogenous estrogen (n = 382) who participated in the Diabetes Prevention Program. INTERVENTIONS: Interventions included ILS with the goals of weight reduction of at least 7% of initial weight and 150 min/wk of moderate intensity exercise or metformin or placebo administered 850 mg twice a day. MAIN OUTCOME MEASURES: Intervention-related changes in ESH and associations of changes in ESH and glucose levels were evaluated. RESULTS:ILS significantly increased SHBG and decreased DHEA before and after adjustment for changes in waist circumference and fasting insulin. ILS did not alter estradiol or testosterone. Metformin did not change any ESH. ILS-induced increases in SHBG and declines in DHEA were associated with decreases in FPG and 2-h glucose, and declines in estradiol were associated with decreases in FPG, before and after adjustment for age, FSH, race/ethnicity, changes in waist circumference, and 1/fasting insulin. CONCLUSIONS: Among postmenopausal glucose-intolerant women not using estrogen, ILS increased SHBG levels and lowered DHEA levels. These changes were associated with lower glucose independent of adiposity and insulin. Metformin effects upon ESH were not significant.
RCT Entities:
CONTEXT: Whether endogenous sex hormones (ESH) [SHBG, estradiol, testosterone, and dehydroepiandrosterone (DHEA)] are altered by intensive lifestyle modification (ILS) or metformin and whether such changes affect glucose levels among dysglycemic postmenopausal women is unclear. OBJECTIVES: Our objective was to examine intervention impact on ESH and associations with fasting plasma glucose (FPG) and 2-h glucose changes among postmenopausal glucose-intolerantwomen. DESIGN: We performed a secondary analysis of a randomized controlled trial. PARTICIPANTS: Participants included postmenopausal, overweight, glucose-intolerantwomen not using exogenous estrogen (n = 382) who participated in the Diabetes Prevention Program. INTERVENTIONS: Interventions included ILS with the goals of weight reduction of at least 7% of initial weight and 150 min/wk of moderate intensity exercise or metformin or placebo administered 850 mg twice a day. MAIN OUTCOME MEASURES: Intervention-related changes in ESH and associations of changes in ESH and glucose levels were evaluated. RESULTS: ILS significantly increased SHBG and decreased DHEA before and after adjustment for changes in waist circumference and fasting insulin. ILS did not alter estradiol or testosterone. Metformin did not change any ESH. ILS-induced increases in SHBG and declines in DHEA were associated with decreases in FPG and 2-h glucose, and declines in estradiol were associated with decreases in FPG, before and after adjustment for age, FSH, race/ethnicity, changes in waist circumference, and 1/fasting insulin. CONCLUSIONS: Among postmenopausal glucose-intolerantwomen not using estrogen, ILS increased SHBG levels and lowered DHEA levels. These changes were associated with lower glucose independent of adiposity and insulin. Metformin effects upon ESH were not significant.
Authors: Nicholas L Smith; Joshua I Barzilay; Douglas Shaffer; Peter J Savage; Susan R Heckbert; Lewis H Kuller; Richard A Kronmal; Helaine E Resnick; Bruce M Psaty Journal: Arch Intern Med Date: 2002-01-28
Authors: Jill Crandall; David Schade; Yong Ma; Wilfred Y Fujimoto; Elizabeth Barrett-Connor; Sarah Fowler; Sam Dagogo-Jack; Reubin Andres Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden Journal: J Clin Endocrinol Metab Date: 2009-09-29 Impact factor: 5.958
Authors: Jennifer S Lee; Andrea Z LaCroix; LieLing Wu; Jane A Cauley; Rebecca D Jackson; Charles Kooperberg; Meryl S Leboff; John Robbins; Cora E Lewis; Douglas C Bauer; Steven R Cummings Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Eric L Ding; Yiqing Song; JoAnn E Manson; David J Hunter; Cathy C Lee; Nader Rifai; Julie E Buring; J Michael Gaziano; Simin Liu Journal: N Engl J Med Date: 2009-08-05 Impact factor: 91.245
Authors: Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani Journal: J Clin Endocrinol Metab Date: 2019-04-01 Impact factor: 5.958
Authors: Catherine Kim; Shengchun Kong; Gail A Laughlin; Sherita H Golden; Kieren J Mather; Bin Nan; John F Randolph; Sharon L Edelstein; Fernand Labrie; Elizabeth Buschur; Elizabeth Barrett-Connor Journal: Menopause Date: 2013-04 Impact factor: 2.953
Authors: Catherine Kim; Dana Dabelea; Rita R Kalyani; Costas A Christophi; George A Bray; Xavier Pi-Sunyer; Christine H Darwin; Swaytha Yalamanchi; Elizabeth Barrett-Connor; Sherita Hill Golden; Edward J Boyko Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Catherine Kim; Xavier Pi-Sunyer; Elizabeth Barrett-Connor; Frankie B Stentz; Mary Beth Murphy; Shengchun Kong; Bin Nan; Abbas E Kitabchi Journal: J Clin Endocrinol Metab Date: 2013-05-24 Impact factor: 5.958